Endothelium-derived bone morphogenic protein antagonists may counteract the proatherogenic vascular effects of bone morphogenic protein 4.

Endothelium-derived bone morphogenic protein antagonists may counteract the proatherogenic vascular effects of bone morphogenic protein 4. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Endothelium-derived bone morphogenic protein antagonists may counteract the proatherogenic vascular effects of bone morphogenic protein 4. Abstract Text:

Kyunghwa Chang,Daiana Weiss,Jin Suo,J David Vega,Don Giddens,W Robert Taylor,Hanjoong Jo,

Endothelium-derived bone morphogenic protein antagonists may counteract the proatherogenic vascular effects of bone morphogenic protein 4. Publishing Authors By Initials

K Chang,D Weiss,J Suo,JD Vega,D Giddens,WR Taylor,H Jo,

For similar cardiovascular diseases: vascular diseases research abstracts see: cardiovascular diseases: vascular diseases research

PUBMED ID PMID:

MEDLINE DATE:

Endothelium-derived bone morphogenic protein antagonists may counteract the proatherogenic vascular effects of bone morphogenic protein 4. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Circulation

VOLUME: 116

Page Numbers: 1221-3

Journal Abbreviation: Circulation

ISSN: 1524-4539

DAY: 11

MONTH: Sep

YEAR: 2007

Endothelium-derived bone morphogenic protein antagonists may counteract the proatherogenic vascular effects of bone morphogenic protein 4. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 147763

Endothelium-derived bone morphogenic protein antagonists may counteract the proatherogenic vascular effects of bone morphogenic protein 4. Keywords Mesh Terms:

KEYWORDS: Vascular Diseases

MESH TERMS: prevention & control

Chemical & Substance for Abstract: Endothelium-derived bone morphogenic protein antagonists may counteract the proatherogenic vascular effects of bone morphogenic protein 4. Information

Substance Name: Acetylcholine

Registry Number: 51-84-3

Grant and Affiliation Information for Endothelium-derived bone morphogenic protein antagonists may counteract the proatherogenic vascular effects of bone morphogenic protein 4.

AFFILIATION:

Country: United States

AGENCY: United States NHLBI

GRANT: HL077256

ACRONYM: HL

MEDLINETA: Circulation

REFSOURCE: Circulation. 2007 Sep 11;116(11):1258-66

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Endothelium-derived bone morphogenic protein antagonists may counteract the proatherogenic vascular effects of bone morphogenic protein 4 Related Publications

• Antipsychotic prescription patterns in outpatient settings: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
• Cigarette smoke-induced proinflammatory alterations in the endothelial phenotype: role of NAD(P)H oxidase activation.
• Clinical and social correlates with the use of depot antipsychotic drugs in outpatients with schizophrenia in China.
• Clinical and social determinants of long-term use of benzodiazepines and its impact on quality of life of chinese schizophrenia patients.
• Comparison of endothelial function, O2-* and H2O2 production, and vascular oxidative stress resistance between the longest-living rodent, the naked mole rat, and mice.
• Differential proinflammatory and prooxidant effects of bone morphogenetic protein-4 in coronary and pulmonary arterial endothelial cells.
• Endothelial dysfunction and vascular inflammation in Type 2 diabetes: interaction of AGE/RAGE and TNF-{alpha} signaling.
• Endothelium-derived bone morphogenic protein antagonists may counteract the proatherogenic vascular effects of bone morphogenic protein 4.
• Examining item bias in the anxiety subscale of the Hospital Anxiety and Depression Scale in patients with chronic obstructive pulmonary disease.
• Hemoperfusion in the treatment of acute clozapine intoxication in China.
• Impact of sociodemographic and clinical factors on subjective quality of life in schizophrenia patients in Beijing, China.
• Impact of the priority follow-up system on quality of life in Chinese schizophrenia patients.
• Inflammation and endothelial dysfunction during aging: role of NF-{kappa}B.
• Pleiotropic effects of the CB2 cannabinoid receptor activation on human monocyte migration: implications for atherosclerosis and inflammatory diseases.
• Prevalence and socio-demographic correlates of schizophrenia in Beijing, China.
• Resveratrol attenuates TNF-alpha-induced activation of coronary arterial endothelial cells: role of NF-kappaB inhibition.
• Socio-demographic and clinical correlates of lifetime suicide attempts and their impact on quality of life in Chinese schizophrenia patients.
• Subjective quality of life in outpatients with schizophrenia in Hong Kong and Beijing: relationship to socio-demographic and clinical factors.
• The aging kidney: role of endothelial oxidative stress and inflammation.
• The genetical basis of the Leonhardian classification of endogenous psychoses.
• Vascular aging in the longest-living rodent, the naked mole rat.
• Vascular superoxide and hydrogen peroxide production and oxidative stress resistance in two closely related rodent species with disparate longevity.
• Vasculoprotective effects of anti-tumor necrosis factor-alpha treatment in aging.
• Vasoprotective effects of resveratrol and SIRT1: attenuation of cigarette smoke-induced oxidative stress and proinflammatory phenotypic alterations.